PRODUCT INFORMATION UPDATED DAILY
Back to catalogue
Recovery

KPV

5mg vial

KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-melanocyte stimulating hormone (α-MSH). It retains the potent anti-inflammatory activity of the parent hormone without its pigmentation or appetite effects, and is studied across inflammatory bowel disease, dermatological inflammation, mast-cell modulation and wound healing.

Select size

Checking availability…

Researched for

  • Broad anti-inflammatory activity via NF-κB suppression
  • Improved outcomes in IBD and colitis animal models
  • Reduced inflammatory dermatological lesions in research
  • Mast-cell stabilisation relevant to allergic and MCAS research
  • Antimicrobial activity against several common pathogens
  • Favourable tolerability with minimal reported side effects

Mechanism of action

Enters cells and translocates to the nucleus to inhibit NF-κB activation, suppressing downstream pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6). Also stabilises mast cells and modulates innate immune responses.

Research protocol

Common research protocols use 200–500mcg subcutaneously once daily, or higher oral/encapsulated doses (approx. 500mcg–1mg) for gut-targeted protocols. Cycles typically run 4–8 weeks.

Half-life

Plasma half-life is short (approx. 30–60 minutes); local tissue effects persist longer.

Reconstitution

Reconstitute a 10mg vial with 2–4mL bacteriostatic water for a 2.5–5mg/mL working concentration. Swirl gently.

Storage

Lyophilised: 2–8°C, stable 18–24 months. Reconstituted: 2–8°C, protect from light, use within 30 days.

Research considerations
  • Human RCT data remains limited; most evidence is preclinical or early-phase.
  • Oral bioavailability is modest - encapsulation or compounding is typically required for gut-targeted use.
  • Long-term safety dataset is not yet well characterised.